alexa TEVAR for Uncomplicated Acute Type B Aortic Dissection: What is Success? | OMICS International
ISSN: 2329-6925
Journal of Vascular Medicine & Surgery
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

TEVAR for Uncomplicated Acute Type B Aortic Dissection: What is Success?

Ganesh S Kumpati*

Division of Cardiothoracic Surgery, University of Utah, UT 84132, USA

*Corresponding Author:
Ganesh S Kumpati, MD
Division of Cardiothoracic Surgery
University of Utah, 30 N. 1900 E., #3C-127
Salt Lake City, UT 84132, USA
Tel: (801) 581-5311
Fax: (801) 585-3936
E-mail: [email protected]

Received Date: May 16, 2013; Accepted Date: May 18, 2013; Published Date: May 20, 2013

Citation: Kumpati GS (2013) TEVAR for Uncomplicated Acute Type B Aortic Dissection: What is Success? J Vasc Med Surg 1:e105. doi:10.4172/2329-6925.1000e105

Copyright: © 2013 Kumpati GS. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Vascular Medicine & Surgery

Type B aortic dissection (typically beginning just distal to the left subclavian artery with variable distal propagation) is a commonly identified clinical problem. Acute type B aortic dissection (less than 14 days from onset) is divided into two types: complicated and uncomplicated. For complicated dissections (visceral malperfusion, aortic rupture, symptoms despite maximal medical therapy), endovascular repair has represented a significant advance over open repair options, and represents a major treatment advance [1] for this difficult problem. Following intervention for complicated aortic dissection, there is positive remodeling of the remaining dissected aorta [2].

Although medical therapy has good short term outcome for uncomplicated type B aortic dissection, long term outcome with medical therapy is not good [3]. Late aorta-related morbidity and mortality is related to progressive aneurysmal dilation of the false lumen with late aortic rupture. Once established aneurysmal dilation of the false lumen has occurred, treatment options become difficult, ranging from endovascular intervention with lower morbidity but variable outcome to open surgery with higher morbidity but excellent long term outcome. Thus, the ideal endovascular intervention would eliminate the aortic dissection early enough in the course of the disease to eliminate late aneurysm complications before an open procedure would be necessary.

The INSTEAD trial has attempted to answer this question. At 2 year follow up, the morbidity for the treatment arm (endovascular repair) versus medical therapy were similar [4]. The treatment arm had more patients with stabilization/regression of the false lumen flow. Long term follow up is necessary to see if this reduces aneurysm formation.

The finding that endovascular intervention did not reduce mortality at 2 years as compared to medical therapy is not a surprise. The real issue is whether late mortality from aortic events is reduced by early intervention. The ability to perform minimally invasive intervention to prevent a later major procedure is quite appealing. This represents the future of treatment for thoracic aortic disease.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Article Usage

  • Total views: 12030
  • [From(publication date):
    June-2013 - Jul 19, 2018]
  • Breakdown by view type
  • HTML page views : 8206
  • PDF downloads : 3824

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

engineer[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version